Mechanism
Fexofenadine and Montelukast provides a dual mechanism approach for comprehensive control of allergic and inflammatory responses affecting both upper and lower airways.
Fexofenadine:
Fexofenadine is a second-generation, selective peripheral H1-receptor antagonist. It works by blocking the action of histamine, a key mediator released from mast cells during allergic reactions. By inhibiting H1 receptors, it reduces symptoms such as sneezing, itching, rhinorrhea (runny nose), and watery eyes.
Unlike first-generation antihistamines, Fexofenadine does not significantly cross the blood-brain barrier, thus minimizing sedation and central nervous system effects.
Montelukast:
Montelukast is a leukotriene receptor antagonist that selectively blocks cysteinyl leukotriene type-1 (CysLT1) receptors in the airways. Leukotrienes (LTC4, LTD4, LTE4) are potent inflammatory mediators released from mast cells and eosinophils, responsible for bronchoconstriction, mucus secretion, vascular permeability, and airway edema.
By inhibiting leukotriene activity, Montelukast reduces airway inflammation, prevents bronchospasm, and improves airflow, making it particularly effective in allergic rhinitis associated with asthma.
Pharmacokinetics
- Absorption: Fexofenadine is rapidly absorbed after oral administration, reaching peak plasma concentration (Tmax) within 2–3 hours.
Montelukast is also well absorbed, with peak plasma levels achieved within 3–4 hours. Food has minimal effect on Montelukast but may reduce Fexofenadine absorption when taken with fruit juices (e.g., grapefruit, orange, apple).
- Bioavailability: Fexofenadine exhibits moderate oral bioavailability due to limited intestinal transport.
Montelukast has good oral bioavailability (~60–70%) and shows consistent plasma concentration levels.
- Distribution:
Fexofenadine is approximately 60–70% protein bound and has limited penetration across the blood-brain barrier, reducing sedative effects.
Montelukast is highly protein bound (>99%) and widely distributed in body tissues, particularly in the lungs.
- Metabolism: Fexofenadine undergoes minimal hepatic metabolism and is largely excreted unchanged.
Montelukast is extensively metabolized in the liver via cytochrome P450 enzymes (primarily CYP3A4, CYP2C8, and CYP2C9).
- Elimination: Fexofenadine is primarily eliminated via feces (~80%) and urine (~10%).
Montelukast is excreted mainly through bile in feces.
Side Effects
- Headache
- Dizziness
- Nausea
- Dry mouth
- Fatigue
Contraindication
- Hypersensitivity to either component
- Severe liver impairment (caution)
Interaction
- Antacids (affect Fexofenadine absorption)
- CYP enzyme modulators (affect Montelukast)
Warning and Precautions
- Use cautiously in hepatic impairment
- Not for acute asthma attacks
- Avoid fruit juices with Fexofenadine
- Use under medical supervision
